U.S. Pharma Stock News

High interest rates, rising oil prices and concerns around an AI-fueled bubble are making many investors rethink how much risk they really want in their portfolios. Instead of chasing the hottest stories, some are looking at larger companies that historically show calmer price swings and stronger balance sheets. This article focuses on three stocks from a low volatility screener that appear particularly exposed to these macro trends and could either help cushion the bumps or feel the strain...

Ouster (OUST) has put its Rev8 digital lidar platform at the center of several recent moves, including an expanded manufacturing partnership, a new BlueCity traffic solution, and fresh robotics collaborations that spotlight its multi-sector ambitions. See our latest analysis for Ouster. These product launches and manufacturing moves have arrived alongside strong trading momentum, with a 1-day share price return of 13.52% and a 90-day share price return of 111.22%. The 1-year total shareholder...

In recent updates, Northrop Grumman reported a record backlog of US$95.61 billion, highlighted improved economics on its B‑21 bomber program, and reaffirmed full‑year sales and earnings guidance despite an operating cash outflow in the first quarter of 2026. Beyond headline backlog growth, the shift of the B‑21 program from loss to operating income suggests maturing execution on one of Northrop Grumman’s most critical long‑cycle defense platforms. Next, we’ll examine how the record...

nCino (NCNO) is back in focus after quarterly revenue came in above analyst expectations, and management underscored rising customer confidence in its AI product approach and long term technology partnerships. See our latest analysis for nCino. Despite the upbeat quarterly update and growing interest in nCino's AI roadmap, the stock has slipped recently, with the share price down 40.2% year to date and the 1 year total shareholder return down 45.2%. This points to fading momentum as investors...

In June 2026, Anterix reported fourth-quarter sales of US$1.96 million and full-year sales of US$6.50 million, with net income rising to US$18.52 million for the quarter and US$90.64 million for the year, alongside the completion of a share repurchase program totaling 691,534 shares for US$23.26 million. Beyond the headline figures, Anterix’s shift to profitability, new utility contracts for its Private LTE and spectrum solutions, and a cash balance above US$98 million with no debt...

In recent days, Mirum Pharmaceuticals and Incyte reported pivotal data and regulatory progress across several programmes, including positive Phase 3 frontMIND results for tafasitamab in high‑risk DLBCL/HGBL, pivotal Phase 2 PROGRESS data and FDA Priority Review for zilurgisertib in FOP, and updated Phase 1 data for INCA033989 in MF and ET. Taken together, these updates highlight Incyte’s attempt to build a broader oncology and rare‑disease portfolio that is less dependent on any single...

NIO (NYSE:NIO) is back in focus after CEO William Li cautioned that China’s auto market could shrink 15% to 20% this year, while reiterating the company’s target for 40% to 50% sales growth. See our latest analysis for NIO. The stock’s recent momentum has cooled, with the share price down 14.75% over the past month and 12.75% over the past 90 days. However, the 1-year total shareholder return of 47.73% still points to a materially stronger longer term performance than its shorter term share...

Earlier in June 2026, Veeva Systems reported first-quarter revenue of US$882.95 million and net income of US$260.94 million, raised its full-year revenue outlook to about US$3.64 billion, and highlighted expanding AI offerings including Vault AI and the upcoming Falcon agentic labor platform. Complementing these updates, UCB’s decision to roll out Veeva’s Safety Suite globally and other large pharma moves toward agentic AI signal growing traction for Veeva’s compliance-focused cloud and...

Earlier this month, Celcuity Inc. priced an upsized US$500,000,000 offering of 0.250% convertible senior notes due 2032 and outlined plans to use the proceeds to repay existing debt and fund working capital, clinical development, potential commercialization and possible future acquisitions. In parallel, Celcuity reported detailed Phase 3 VIKTORIA-1 data showing gedatolisib-based regimens improved progression-free outcomes versus alpelisib plus fulvestrant in PIK3CA mutant advanced breast...

Why Baidu (NasdaqGS:BIDU) is back in focus after Switzerland’s Apollo Go permit Baidu (NasdaqGS:BIDU) is in the spotlight after Switzerland’s Federal Roads Office granted a special permit for Level 4 autonomous operations. This allows its Apollo Go powered AmiGo service to run trials in Eastern Switzerland. This permit supports Baidu’s push to apply its autonomous driving system in real world European conditions, with open road testing already underway across an approximately 80 km service...

Earlier this month, Nu Holdings Ltd. authorized a US$1.00 billion share repurchase program over 12 months, to be funded from retained and future earnings, with repurchased shares held in treasury or canceled. This sizable buyback, paired with ongoing international expansion and upcoming leadership changes including a new Global CFO, highlights how management is reshaping capital allocation while scaling the business. With that in mind, we’ll now examine how the new US$1.00 billion buyback...

AGNC Investment (AGNC) has drawn fresh attention after recent trading left the stock with a value score of 5 and an intrinsic discount of about 41%, prompting investors to reassess its income focused mortgage REIT profile. See our latest analysis for AGNC Investment. At a share price of US$10.46, AGNC’s recent 1 day share price return of 1.45% and 7 day share price return of 3.46% sit against a year to date share price decline of 4.30%. Its 1 year total shareholder return of 28.99% and 3 year...

Why Main Street Capital Is Back On Income Investors’ Radar Main Street Capital (MAIN) has drawn fresh attention after recent price moves left the stock down year to date and over the past 3 months, despite a gain over the past month. See our latest analysis for Main Street Capital. At a share price of $51.29, Main Street Capital’s recent performance has been mixed, with the share price down year to date and over 90 days, while multi year total shareholder returns remain positive. This...

In the past, multiple law firms, including Faruqi & Faruqi and Glancy Prongay Wolke & Rotter, filed federal securities class action lawsuits against Globant S.A., alleging that the company misled investors about its Latin American operations between February 15, 2024 and August 14, 2025. The complaints focus on claims that Globant concealed weakening demand, wage freezes and project cancellations in Latin America, raising questions about prior management commentary and disclosure...

With inflation readings running hot, producer costs climbing, and interest rates holding steady, many investors are rethinking how to position around essential services and pricing power. Utilities can sit at an interesting crossroads when energy prices and input costs move, and not all stocks react in the same way to these pressures. This article focuses on three US utilities stocks from our screener that appear especially exposed to the current inflation and rate backdrop. You will see how...

In recent weeks, Atlanticus Holdings has attracted fresh attention after a strong run of positive earnings surprises and favorable analyst estimate revisions, underscoring its position as a profitable provider of credit technology and services to underserved consumers. At the same time, mixed signals such as a multi-year dip in earnings per share, concerns about financial strength, and insider selling highlight that the company’s improving sentiment is balanced by operational and funding...

Webull has rolled out a Model Context Protocol (MCP) server that lets retail investors use natural language to access trading tools and place orders. The launch is aimed at bringing AI powered, context aware trading capabilities to a broader set of Webull users, not just developers and quant focused traders. MCP is designed to connect everyday investors to real time data and execution through simple text based prompts inside the Webull platform. For investors watching Webull, ticker...

American Healthcare REIT Inc. recently priced an underwritten public offering of 14,000,000 common shares, tied to a forward sale agreement with the underwriter, which is expected to raise approximately US$705.6 million in gross proceeds before expenses for general corporate purposes and potential future investments. This large equity raise and use of a forward sale structure highlights management’s focus on securing flexible funding for future healthcare real estate opportunities while...

The Glazer family is reviewing options around a potential sale of its majority stake in Manchester United (NYSE:MANU). Internal ownership discussions have intensified, with fan protests and long-running discontent forming part of the backdrop. A full sale could reshape control of the club and affect the position of minority stakeholder INEOS. For investors, Manchester United is both a football club and a global entertainment business, with revenue streams linked to matchday, broadcasting,...

CrowdStrike recently reported first-quarter fiscal 2027 results with revenue of US$1,385.63 million and a shift from a US$104.26 million net loss to US$27.77 million in net income, raised its full‑year revenue guidance, and introduced new AI-focused offerings such as Continuous Identity for AI Agents while appointing a Chief AI and Autonomous Systems Officer. Together with expanded alliances like the deeper collaboration with Cognizant and membership in identity standards bodies, these...

On June 5, 2026, Grindr Inc. and Warner Records Inc. hosted a global in-app livestream of Madonna premiering three Confessions II tracks, transforming midtown Manhattan into a "Global Gayborhood" with multi-angle coverage, live dancers, and immersive in-app experiences for millions of users worldwide. Alongside this cultural partnership, Grindr filed a US$124.12 million shelf registration for 11,600,000 common shares tied to an ESOP-related offering, underscoring how content-driven...

In the past quarter, CDW Corporation reported Q1 2026 results showing revenue growth but weaker operating income due to margin pressure from a heavier mix of lower-margin hardware and reduced contribution from higher-margin cloud and SaaS revenues. This shift in revenue mix highlights how sensitive CDW’s profitability can be to balance between transactional hardware sales and higher-margin subscription-based services. Next, we’ll examine how this recent margin pressure from a hardware-heavy...

Dyne Therapeutics recently completed enrollment of the 71‑patient registrational expansion cohort in its global Phase 1/2 ACHIEVE trial of investigational DM1 therapy z‑basivarsen, while shareholders approved doubling authorized common stock to 400,000,000 shares. This trial milestone positions Dyne to pursue accelerated approval pathways for z‑basivarsen in a disease area with no approved disease‑modifying treatments. Next, we’ll examine how completing enrollment in the registrational...

Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 data for lupus drug dapirolizumab pegol highlighted progress across its pipeline. See our latest analysis for Biogen. These pipeline updates come after a stronger period for the stock, with an 8.96% 90 day share price return and a 56.95% 1 year total shareholder return, in contrast with weaker three and five year total shareholder...